Statins: The Dispensing Safety Checklist

📋 First Dispense Essentials

Mandatory items to issue

• Patient information leaflet supplied with the medicine. Confirm patient has received it.
• Verbal counselling on muscle symptoms: patients must report unexplained muscle pain, weakness, or tenderness, particularly if accompanied by dark urine.
• Advise on grapefruit: large amounts of grapefruit or grapefruit juice can significantly raise simvastatin and atorvastatin levels.

Baseline clinical checks

• Liver function tests (LFTs) before starting. Statins are generally avoided in active liver disease.
• Fasting lipid profile to establish a baseline for monitoring treatment response.
• Creatine kinase (CK) at baseline if the patient has risk factors for myopathy: older age, hypothyroidism, renal impairment, personal or family history of muscle disorders, or high alcohol intake.
• Thyroid function: untreated hypothyroidism significantly increases the risk of statin-related myopathy. Confirm thyroid function has been checked if relevant.
• Confirm the patient is not pregnant, planning pregnancy, or suspects pregnancy.

Key risks and lifestyle traps

• Simvastatin dose caps: when prescribed alongside amlodipine or diltiazem the maximum simvastatin dose is 20 mg; with amiodarone or verapamil it is also 20 mg. The combination with gemfibrozil is contraindicated due to severe myopathy risk.
• Macrolide antibiotics (clarithromycin, erythromycin): can substantially increase simvastatin and atorvastatin levels and raise the risk of muscle toxicity. Check whether the patient has been advised to temporarily stop the statin during the antibiotic course. If no advice has been given, seek clarification before dispensing.
• Ciclosporin, and to a lesser extent tacrolimus, can increase statin exposure and the risk of muscle toxicity. These combinations require specialist oversight.
• Grapefruit juice in large amounts can significantly increase simvastatin and atorvastatin levels. Rosuvastatin and pravastatin are not affected.
• Warfarin: statins, particularly fluvastatin and rosuvastatin, may increase anticoagulant effect. Check that International Normalised Ratio (INR) monitoring is up to date if the patient is taking warfarin.
• Pregnancy: statins should not be used during pregnancy. If the patient is pregnant, planning pregnancy, or suspects pregnancy, refer urgently to the prescriber.
• Alcohol: regular heavy alcohol intake increases the risk of liver toxicity. Advise moderation.

First dispense script

🔄 Repeat Dispense Screen

Mandatory documentation

• Record the date of the last liver function test (LFT) result on the dispensing record. Flag if overdue.
• Note any dose changes from the previous prescription, particularly for simvastatin (dose caps apply with several common medicines).
• Document any new interacting medicines added since the last dispense.

Ongoing clinical checks

• Liver function tests: at baseline, within 3 months of starting treatment, and at 12 months. Further testing is only needed if clinically indicated or symptoms suggest liver injury.
• Lipid profile: after starting treatment and periodically thereafter to assess response.
• Creatine kinase (CK): only if the patient reports muscle symptoms. Routine monitoring is not recommended in patients without symptoms.
• In patients taking warfarin: check that International Normalised Ratio (INR) monitoring has been reviewed after any statin dose change or statin switch.

Ask the patient at the counter

• "Have you had any unexplained muscle pain, weakness, or tenderness since your last prescription?"
• "Have you started any new medicines, including antibiotics, antifungals, medicines from a hospital clinic, or herbal remedies?"

Lifestyle and surgical alerts

• New or significantly increased exercise: intensive or unfamiliar exercise alongside statin treatment can increase the risk of muscle injury. Advise patients to increase activity gradually and report unusual muscle symptoms.
• Pregnancy or planning pregnancy: statins should be stopped and the prescriber contacted promptly.
• Alcohol: consistent moderate intake is preferable. Heavy or binge drinking increases the risk of liver toxicity.
• Grapefruit: patients taking simvastatin or atorvastatin should avoid large or regular amounts of grapefruit or grapefruit juice.

Download the checklist